DNLI EBITDA | Denali Therapeutics Inc.

Denali Therapeutics Inc. (DNLI) EBITDA

2026-06-30: Basis Reported; EBITDA -$126.97M*; Operating income -$130.54M; Depreciation and amortization $3.57M*.
2026-03-31: Basis Reported; EBITDA -$134.51M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$134.5M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$134.49M*; Operating income -$137.43M; Depreciation and amortization $2.95M*.

Complete source-backed ebitda history.

Available history: 2016-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$126.97M*	-$130.54M	$3.57M*	$3.60M	-3523.09%*	$805.00K*	-$97.00M*	$93.00K	$97.02M	$36.28M	(m)
2026-03-31	Reported	-$134.51M	(m)	(m)	(m)	(m)	$2.47M	-$131.20M	(m)	$103.85M	(m)	(m)
2025-12-31	Reported	-$134.5M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$134.49M*	-$137.43M	$2.95M*	(m)	(m)	-$1.38M*	-$107.30M*	(m)	$101.95M	(m)	(m)
2025-06-30	Reported	-$131.92M*	-$134.96M	$3.04M*	$0.00	(m)	$4.28M*	-$75.30M*	$0.00	$102.70M	$32.27M	(m)
2025-03-31	Reported	-$143.26M	(m)	(m)	(m)	(m)	$5.08M	-$131.47M	(m)	$116.23M	(m)	(m)
2024-12-31	Reported	-$127.99M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$121.35M*	-$123.19M	$1.84M*	$0.00	(m)	$3.88M*	-$59.14M*	(m)	$98.24M	(m)	(m)
2024-06-30	Reported	-$114.65M*	-$116.59M	$1.94M*	$0.00	(m)	$4.79M*	-$91.22M*	(m)	$91.40M	(m)	(m)
2024-03-31	Reported	-$115.55M	(m)	(m)	(m)	(m)	$2.15M	-$113.62M	(m)	$107.02M	(m)	(m)
2023-12-31	Reported	-$130.4M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$111.58M*	-$113.80M	$2.22M*	$1.27M	-8806.47%*	$2.07M*	-$87.36M*	(m)	$89.74M	(m)	$0.00
2023-06-30	Reported	$172.77M*	$170.48M	$2.29M*	$294.12M	58.74%*	$5.85M*	-$113.17M*	(m)	$97.52M	(m)	$0.00
2023-03-31	Reported	-$110.77M	(m)	(m)	(m)	(m)	$2.79M	-$58.80M	(m)	$128.82M	(m)	(m)
2022-12-31	Reported	-$101.25M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$105.34M*	-$107.49M	$2.14M*	$184.00K	-57252.72%*	$6.05M*	-$57.05M*	(m)	$87.79M	(m)	$0.00
2022-06-30	Reported	-$59.34M*	-$61.42M	$2.07M*	$52.48M	-113.08%*	$2.89M*	-$42.90M*	(m)	$92.74M	(m)	$27.00K
2022-03-31	Reported	-$64.42M	(m)	(m)	(m)	(m)	$4.04M	-$72.11M	(m)	$86.10M	(m)	(m)
2021-12-31	Reported	-$75.03M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$83.41M*	-$85.59M	$2.19M*	$5.29M	-1578.16%*	$1.88M*	-$41.43M*	(m)	$71.56M	(m)	$0.00
2021-06-30	Reported	-$59.61M*	-$61.82M	$2.20M*	$22.94M	-259.91%*	$772.00K*	-$54.22M*	(m)	$65.71M	(m)	$0.00
2021-03-31	Reported	-$69.11M	(m)	(m)	(m)	(m)	$2.80M	-$50.24M	(m)	$60.21M	(m)	$0.00
2020-12-31	Reported	$246.2M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$57.96M*	-$60.12M	$2.16M*	$9.39M	-617.38%*	$706.00K*	$86.00K*	(m)	$53.70M	(m)	$56.00K
2020-06-30	Reported	-$59.13M*	-$61.28M	$2.15M*	$5.81M	-1017.59%*	$315.00K*	-$43.36M*	(m)	$53.15M	(m)	$79.00K
2020-03-31	Reported	-$57.86M	(m)	(m)	(m)	(m)	$879.00K	-$54.49M	(m)	$51.02M	(m)	-$135.00K
2019-12-31	Reported	-$55.7M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$48.27M*	-$50.16M	$1.89M*	$13.51M	-357.31%*	$2.85M*	-$30.43M*	(m)	$52.54M	(m)	-$113.00K
2019-06-30	Reported	-$61.12M*	-$62.76M	$1.64M*	$4.10M	-1491.46%*	$10.27M*	-$43.17M*	(m)	$51.88M	(m)	-$313.00K
2019-03-31	Reported	-$40.11M	(m)	(m)	(m)	(m)	$2.03M	-$30.32M	(m)	$37.40M	(m)	$0.00
2018-12-31	Reported	$77.1M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$35.64M*	-$37.96M	$2.33M*	$1.20M	-2982.18%*	$847.00K*	-$34.82M*	(m)	$30.32M	(m)	$0.00
2018-06-30	Reported	-$55.53M*	-$57.38M	$1.85M*	$1.65M	-3369.36%*	$572.00K*	-$41.82M*	(m)	$52.13M	(m)	$0.00
2018-03-31	Reported	-$24.89M	(m)	(m)	(m)	(m)	$537.00K	$33.58M	(m)	$20.82M	(m)	(m)
2017-12-31	Reported	(m)	-$23.54M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	(m)	-$22.29M	(m)	$0.00	(m)	$367.00K*	(m)	(m)	$18.52M	(m)	(m)
2017-06-30	Reported	(m)	-$22.57M	(m)	$0.00	(m)	$569.00K*	(m)	(m)	$19.00M	(m)	(m)
2017-03-31	Reported	(m)	-$21.74M	(m)	(m)	(m)	$868.00K	(m)	(m)	$18.47M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$544.16M	(m)	(m)	(m)	(m)	$9.50M	-$412.60M	(m)	$418.78M	(m)	$102.00K
2024-12-31	Reported	-$479.55M	(m)	(m)	(m)	(m)	$15.91M	-$347.69M	(m)	$396.44M	(m)	$68.00K
2023-12-31	Reported	-$179.97M	(m)	(m)	(m)	(m)	$12.94M	-$357.99M	(m)	$423.88M	(m)	$30.00K
2022-12-31	Reported	-$330.36M	(m)	(m)	(m)	(m)	$17.83M	-$244.72M	(m)	$358.73M	(m)	$21.00K
2021-12-31	Reported	-$287.16M	(m)	(m)	(m)	(m)	$8.50M	-$211.39M	(m)	$265.35M	(m)	-$575.00K
2020-12-31	Reported	$71.25M	(m)	(m)	(m)	(m)	$3.10M	$416.15M	(m)	$212.62M	(m)	$823.00K
2020-09-30	Rolling	(m)	-$239.12M*	(m)	$23.42M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$229.16M*	(m)	$27.54M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$230.64M*	(m)	$25.83M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$205.19M	(m)	(m)	(m)	(m)	$17.92M	-$151.58M	(m)	$193.38M	(m)	-$351.00K
2019-12-31	Rolling	(m)	-$213.18M*	(m)	$26.39M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$80.70M*	(m)	$147.39M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$68.51M*	(m)	$135.08M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$63.13M*	(m)	$132.63M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$38.96M	(m)	(m)	(m)	(m)	$3.39M	$50.12M	(m)	$143.18M	(m)	$0.00
2018-12-31	Rolling	(m)	-$46.37M*	(m)	$129.16M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$144.63M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$128.96M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$94.14M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$87.06M	(m)	(m)	(m)	(m)	$2.88M	-$76.64M	(m)	$74.46M	(m)	$0.00
2017-12-31	Rolling	(m)	-$90.14M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	-$85.96M	(m)	(m)	(m)	(m)	$6.13M	-$71.91M	(m)	$75.70M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Tarsus Pharmaceuticals, Inc. (TARS)	United States	$3.329B	-58.60
Relay Therapeutics, Inc. (RLAY)	United States	$3.884B	-14.30
Beam Therapeutics Inc. (BEAM)	United States	$2.549B	-41.51
Greenland Mines Ltd (GRML)	United States	$2.362B
BIOCRYST PHARMACEUTICALS INC (BCRX)	United States	$2.175B	-6.63
ADMA BIOLOGICS, INC. (ADMA)	United States	$2.131B	11.16
Kodiak Sciences Inc. (KOD)	United States	$2.090B	-10.12
RECURSION PHARMACEUTICALS, INC. (RXRX)	United States	$2.080B	-3.78
Vericel Corp (VCEL)	United States	$2.011B	93.97
Adaptive Biotechnologies Corp (ADPT)	United States	$4.719B	-53.43